Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Fibroblast Growth Factor 21 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:FGF-21, UNQ3115/PRO10196
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD191108200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma

Sample Requirements

75 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under this condition, the kit is stable until the expiration date (see the label on the box).

Calibration Curve

Calibration Range

30–1920 pg/ml

Limit of Detection

7 pg/ml

Intra-assay (Within-Run)

n = 6; CV = 2.0 %

Inter-assay (Run-to-Run)

n = 6; CV = 3.3 %

Spiking Recovery

100.4 %

Dilution Linearity

102.1 %

Crossreactivity

  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • mouse Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
  • monkey Yes (recommended dilution 1:2)
Summary

Features

  • It is intended for research use only
  • The total assay time is less than 3.5 hours
  • The kit measures FGF-21 in serum, plasma (EDTA, citrate, heparin)
  • Assay format - 96 wells
  • Quality controls are human serum based
  • Standard is recombinant protein based
  • Components of kit are provided ready to use, concentrated, lyophilized or in liquid form

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation

Summary

The fibroblast growth factor family (FGFs) are a family of more than 20 small (17-26 kDa) secreted peptides. The initial characterisation of these proteins focused on their ability to stimulate fibroblast proliferation through FGF receptors (FGFRs). Members of FGFs family play important roles in defining and regulating the development and function of endocrine tissues as well as modulating various metabolic processes.
A recently described member of FGFs family, FGF-21, also called Fibroblast growth factor 21 precursor and UNQ3115/PRO10196, has been characterised as a potent metabolic regulator. FGF-21 is preferentially expressed in liver and regulates glucose uptake in human fat cells. Moreover, therapeutic administration of FGF-21 decreased plasma glucose levels and triglycerides to near normal levels in multiple mouse models of type 2 diabetes. Short-term treatment of normal or db/db mice with FGF-21 lowered plasma levels of insulin and improved glucose clearance compared with vehicle after oral glucose tolerance testing. Constant infusion of FGF-21 for 8 weeks in db/db mice nearly normalized fed blood glucose levels and increased plasma insulin levels. When administrated daily for 6 weeks to diabetic rhesus monkeys, FGF-21 caused dramatic decline in fasting plasma glucose, fructosamine, triglicerides, insulin, and glucagon. FGF-21 administration also led to significant improvements in lipoprotein profiles, including lowering of low-density lipoprotein cholesterol and raising of high-density lipoprotein cholesterol as well as beneficial changes in the circulating levels of several cardiovascular risk factors.
FGF-21, when overexpressed, protected animals from diet-induced obesity. These results define a functional role for FGF-21 in vivo and provide evidence that FGF-21 can lower glucose and triglyceride levels in diabetic animals.
In contrast to several members of the FGF family which may induce therapeutically undesirable in vivo proliferation of various cell types, a recent study demonstrated that FGF-21 did not induce mitogenicity, hypoglycemia or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, FGF-21 appears to have considerable potential for the treatment of diabetes mellitus.

Areas of investigation:
Lipid metabolism, Diabetes mellitus type 2, Metabolic syndrome

Product References (71)

References

  • Ahola S, Auranen M, Isohanni P, Niemisalo S, Urho N, Buzkova J, Velagapudi V, Lundbom N, Hakkarainen A, Muurinen T, Piirilä P, Pietiläinen KH, Suomalainen A.Modified Atkins diet induces subacute selective ragged-red-fiber lysis inmitochondrial myopathy patients. EMBO Mol Med. 2016 Nov 2;8(11):1234-1247. doi:10.15252/emmm.201606592. Print 2016 Nov. PubMed PMID: 27647878; PubMed CentralPMCID: PMC5090657. See more on PubMed
  • Bisgaard A, Sørensen K, Johannsen TH, Helge JW, Andersson AM, Juul A.Significant gender difference in serum levels of fibroblast growth factor 21 inDanish children and adolescents. Int J Pediatr Endocrinol. 2014;2014(1):7. doi:10.1186/1687-9856-2014-7. Epub 2014 May 23. PubMed PMID: 24883065; PubMed CentralPMCID: PMC4039053. See more on PubMed
  • Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, Ding X,Elmquist JK, Takahashi JS, Mangelsdorf DJ, Kliewer SA. FGF21 regulates metabolismand circadian behavior by acting on the nervous system. Nat Med. 2013Sep;19(9):1147-52. doi: 10.1038/nm.3249. Epub 2013 Aug 11. PubMed PMID: 23933984;PubMed Central PMCID: PMC3769420. See more on PubMed
  • Chen H, Lu N, Zheng M. A high circulating FGF21 level as a prognostic markerin patients with acute myocardial infarction. Am J Transl Res. 2018 Sep15;10(9):2958-2966. eCollection 2018. PubMed PMID: 30323882; PubMed CentralPMCID: PMC6176227. See more on PubMed
  • Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulatingfibroblast growth factor 21 is induced by peroxisome proliferator-activatedreceptor agonists but not ketosis in man. J Clin Endocrinol Metab. 2009Sep;94(9):3594-601. doi: 10.1210/jc.2009-0111. Epub 2009 Jun 16. PubMed PMID:19531592. See more on PubMed
  • Crooks DR, Natarajan TG, Jeong SY, Chen C, Park SY, Huang H, Ghosh MC, TongWH, Haller RG, Wu C, Rouault TA. Elevated FGF21 secretion, PGC-1α and ketogenicenzyme expression are hallmarks of iron-sulfur cluster depletion in humanskeletal muscle. Hum Mol Genet. 2014 Jan 1;23(1):24-39. doi: 10.1093/hmg/ddt393. Epub 2013 Aug 13. PubMed PMID: 23943793; PubMed Central PMCID: PMC3857942. See more on PubMed
  • Cuevas-Ramos D, Almeda-Valdes P, Gómez-Pérez FJ, Meza-Arana CE, Cruz-Bautista I, Arellano-Campos O, Navarrete-López M, Aguilar-Salinas CA. Daily physicalactivity, fasting glucose, uric acid, and body mass index are independent factorsassociated with serum fibroblast growth factor 21 levels. Eur J Endocrinol. 2010 Sep;163(3):469-77. doi: 10.1530/EJE-10-0454. Epub 2010 Jun 21. PubMed PMID:20566587. See more on PubMed
  • Cuevas-Ramos D, Almeda-Valdés P, Meza-Arana CE, Brito-Córdova G, Gómez-PérezFJ, Mehta R, Oseguera-Moguel J, Aguilar-Salinas CA. Exercise increases serumfibroblast growth factor 21 (FGF21) levels. PLoS One. 2012;7(5):e38022. doi:10.1371/journal.pone.0038022. Epub 2012 May 31. PubMed PMID: 22701542; PubMedCentral PMCID: PMC3365112. See more on PubMed
  • Dostálová I, Haluzíková D, Haluzík M. Fibroblast growth factor 21: a novelmetabolic regulator with potential therapeutic properties in obesity/type 2diabetes mellitus. Physiol Res. 2009;58(1):1-7. Review. PubMed PMID: 19331512. See more on PubMed
  • Dostálová I, Kaválková P, Haluzíková D, Lacinová Z, Mráz M, Papezová H,Haluzík M. Plasma concentrations of fibroblast growth factors 19 and 21 inpatients with anorexia nervosa. J Clin Endocrinol Metab. 2008 Sep;93(9):3627-32. doi: 10.1210/jc.2008-0746. Epub 2008 Jun 17. PubMed PMID: 18559909. See more on PubMed
  • Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growthfactor-21 may mediate growth hormone resistance in anorexia nervosa. J ClinEndocrinol Metab. 2010 Jan;95(1):369-74. doi: 10.1210/jc.2009-1730. Epub 2009 Nov19. PubMed PMID: 19926712; PubMed Central PMCID: PMC2805486. See more on PubMed
  • Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS,Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistantstate. Diabetes. 2010 Nov;59(11):2781-9. doi: 10.2337/db10-0193. Epub 2010 Aug 3.PubMed PMID: 20682689; PubMed Central PMCID: PMC2963536. See more on PubMed
  • Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, Kharitonenkov A, Schuppan D, Flier JS, Maratos-Flier E. Fibroblast growth factor 21 limitslipotoxicity by promoting hepatic fatty acid activation in mice on methionine andcholine-deficient diets. Gastroenterology. 2014 Nov;147(5):1073-83.e6. doi:10.1053/j.gastro.2014.07.044. Epub 2014 Jul 30. PubMed PMID: 25083607; PubMedCentral PMCID: PMC4570569. See more on PubMed
  • Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, Domingo P, Giralt M, FrühbeckG, Villarroya F. Opposite alterations in FGF21 and FGF19 levels and disturbedexpression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond). 2015 Jan;39(1):121-9. doi: 10.1038/ijo.2014.76. Epub 2014 May 12.PubMed PMID: 24813368. See more on PubMed
  • Gariani K, Drifte G, Dunn-Siegrist I, Pugin J, Jornayvaz FR. Increased FGF21plasma levels in humans with sepsis and SIRS. Endocr Connect. 2013 Sep17;2(3):146-53. doi: 10.1530/EC-13-0040. Print 2013. PubMed PMID: 23999826;PubMed Central PMCID: PMC3845842. See more on PubMed
  • Guasti L, Silvennoinen S, Bulstrode NW, Ferretti P, Sankilampi U, Dunkel L.Elevated FGF21 leads to attenuated postnatal linear growth in preterm infantsthrough GH resistance in chondrocytes. J Clin Endocrinol Metab. 2014Nov;99(11):E2198-206. doi: 10.1210/jc.2014-1566. Epub 2014 Aug 19. PubMed PMID:25137423. See more on PubMed
  • Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, Moon MK, Lee HK, Kang SW, Han DS, Kim YB, Jang HC, Park KS. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renaldisease patients receiving long-term peritoneal dialysis. Metabolism. 2010Nov;59(11):1656-62. doi: 10.1016/j.metabol.2010.03.018. Epub 2010 Apr 27. PubMed PMID: 20423749. See more on PubMed
  • Hero M, Dunkel L, Vaaralahti K, Raivio T. Serum FGF21 in boys with idiopathic short stature: relationship to lipid profile, onset of puberty and growth. ClinEndocrinol (Oxf). 2011 Jul;75(1):141-2. doi: 10.1111/j.1365-2265.2011.03999.x.PubMed PMID: 21521270. See more on PubMed
  • Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T,Nielsen S, Pedersen BK. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes. 2009 Dec;58(12):2797-801. doi:10.2337/db09-0713. Epub 2009 Aug 31. PubMed PMID: 19720803; PubMed Central PMCID:PMC2780875. See more on PubMed
  • Isaac O, Thiemer K. [Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl)].Arzneimittelforschung. 1975 Sep;25(9):1352-4. German. PubMed PMID: 21. See more on PubMed
  • Jian WX, Peng WH, Jin J, Chen XR, Fang WJ, Wang WX, Qin L, Dong Y, Su Q.Association between serum fibroblast growth factor 21 and diabetic nephropathy.Metabolism. 2012 Jun;61(6):853-9. doi: 10.1016/j.metabol.2011.10.012. Epub 2011Dec 2. PubMed PMID: 22136913. See more on PubMed
  • Jin QR, Bando Y, Miyawaki K, Shikama Y, Kosugi C, Aki N, Funaki M, Noji S.Correlation of fibroblast growth factor 21 serum levels with metabolic parametersin Japanese subjects. J Med Invest. 2014;61(1-2):28-34. PubMed PMID: 24705745. See more on PubMed
  • Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, Sekiguchi C,Miyazawa Y, Kusano E, Kanda Y, Asano Y, Kuro-O M, Nagata D. Association betweencirculating fibroblast growth factor 21 and mortality in end-stage renal disease.PLoS One. 2017 Jun 5;12(6):e0178971. doi: 10.1371/journal.pone.0178971.eCollection 2017. PubMed PMID: 28582462; PubMed Central PMCID: PMC5459464. See more on PubMed
  • Kotulák T, Drápalová J, Kopecký P, Lacinová Z, Kramář P, Říha H, Netuka I,Malý J, Housa D, Bláha J, Svačina Š, Haluzík M. Increased circulating andepicardial adipose tissue mRNA expression of fibroblast growth factor-21 aftercardiac surgery: possible role in postoperative inflammatory response and insulinresistance. Physiol Res. 2011;60(5):757-67. Epub 2011 Aug 1. PubMed PMID:21812521. See more on PubMed
  • Kralisch S, Tönjes A, Krause K, Richter J, Lossner U, Kovacs P, Ebert T,Blüher M, Stumvoll M, Fasshauer M. Fibroblast growth factor-21 serumconcentrations are associated with metabolic and hepatic markers in humans. JEndocrinol. 2013 Jan 18;216(2):135-43. doi: 10.1530/JOE-12-0367. Print 2013 Feb. PubMed PMID: 23129782. See more on PubMed
  • Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, Münzberg H, Hutson SM, Gettys TW, Schwartz MW, Morrison CD. FGF21 is an endocrine signal ofprotein restriction. J Clin Invest. 2014 Sep;124(9):3913-22. doi:10.1172/JCI74915. Epub 2014 Aug 18. PubMed PMID: 25133427; PubMed Central PMCID: PMC4153701. See more on PubMed
  • Lee KJ, Jang YO, Cha SK, Kim MY, Park KS, Eom YW, Baik SK. Expression ofFibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through theNuclear Factor-κB and c-Jun N-Terminal Kinase Pathways. Gut Liver. 2018 Jul15;12(4):449-456. doi: 10.5009/gnl17443. PubMed PMID: 29699061; PubMed CentralPMCID: PMC6027831. See more on PubMed
  • Lenart-Lipińska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J.Serum fibroblast growth factor 21 is predictive of combined cardiovascularmorbidity and mortality in patients with type 2 diabetes at a relativelyshort-term follow-up. Diabetes Res Clin Pract. 2013 Aug;101(2):194-200. doi:10.1016/j.diabres.2013.04.010. Epub 2013 Jun 12. PubMed PMID: 23768789. See more on PubMed
  • Li G, Yin J, Fu J, Li L, Grant SFA, Li C, Li M, Mi J, Li M, Gao S. FGF21deficiency is associated with childhood obesity, insulin resistance andhypoadiponectinaemia: The BCAMS Study. Diabetes Metab. 2017 Jun;43(3):253-260.doi: 10.1016/j.diabet.2016.12.003. Epub 2017 Jan 27. PubMed PMID: 28139438. See more on PubMed
  • Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W. Serum fibroblastgrowth factor 21 is associated with adverse lipid profiles andgamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J ClinEndocrinol Metab. 2009 Jun;94(6):2151-6. doi: 10.1210/jc.2008-2331. Epub 2009 Mar24. PubMed PMID: 19318452. See more on PubMed
  • Li X, Fan X, Ren F, Zhang Y, Shen C, Ren G, Sun J, Zhang N, Wang W, Ning G,Yang J. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract. 2011 Jul;93(1):10-6. doi: 10.1016/j.diabres.2011.02.034.Epub 2011 May 18. PubMed PMID: 21596453. See more on PubMed
  • Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X. Serumlevels of FGF-21 are increased in coronary heart disease patients and areindependently associated with adverse lipid profile. PLoS One. 2010 Dec29;5(12):e15534. doi: 10.1371/journal.pone.0015534. PubMed PMID: 21206918; PubMedCentral PMCID: PMC3012070. See more on PubMed
  • Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, Wang X, Lin S, Feng W, Li X.Circulating FGF21 levels are progressively increased from the early to end stagesof chronic kidney diseases and are associated with renal function in Chinese.PLoS One. 2011 Apr 15;6(4):e18398. doi: 10.1371/journal.pone.0018398. PubMedPMID: 21525989; PubMed Central PMCID: PMC3078122. See more on PubMed
  • Liu Y, Zhao C, Xiao J, Liu L, Zhang M, Wang C, Wu G, Zheng MH, Xu LM, Chen YP,Mohammadi M, Chen SY, Cave M, McClain C, Li X, Feng W. Fibroblast growth factor21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury.Sci Rep. 2016 Aug 8;6:31026. doi: 10.1038/srep31026. PubMed PMID: 27498701;PubMed Central PMCID: PMC4976373. See more on PubMed
  • Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, ZierathJR, Chibalin AV, Moller DE, Kharitonenkov A, Krook A. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes andobesity. Diabetes Metab Res Rev. 2011 Mar;27(3):286-97. doi: 10.1002/dmrr.1177.PubMed PMID: 21309058. See more on PubMed
  • Matuszek B, Lenart-Lipińska M, Duma D, Solski J, Nowakowski A. Evaluation ofconcentrations of FGF-21 - a new adipocytokine in type 2 diabetes. EndokrynolPol. 2010 Jan-Feb;61(1):50-4. PubMed PMID: 20205104. See more on PubMed
  • Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E. Effects of a novel selective peroxisome proliferator-activatedreceptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake inpatients with hypertriglyceridemia and insulin resistance. J Diabetes Investig.2018 Nov;9(6):1323-1332. doi: 10.1111/jdi.12845. Epub 2018 Apr 26. PubMed PMID:29603684; PubMed Central PMCID: PMC6215940. See more on PubMed
  • Miehle K, Ebert T, Kralisch S, Hoffmann A, Kratzsch J, Schlögl H, Stumvoll M, Fasshauer M. Serum concentrations of fibroblast growth factor 21 are elevated in patients with congenital or acquired lipodystrophy. Cytokine. 2016Jul;83:239-244. doi: 10.1016/j.cyto.2016.04.015. Epub 2016 May 11. PubMed PMID:27179139. See more on PubMed
  • Moure R, Domingo P, Villarroya J, Gasa L, Gallego-Escuredo JM, Quesada-LópezT, Morón-Ros S, Maroto AF, Mateo GM, Domingo JC, Villarroya F, Giralt M.Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on theFibroblast Growth Factor 21/β-Klotho System. Antimicrob Agents Chemother. 2018May 25;62(6). pii: e00029-18. doi: 10.1128/AAC.00029-18. Print 2018 Jun. PubMedPMID: 29661866; PubMed Central PMCID: PMC5971578. See more on PubMed
  • Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D,Matoulek M, Dostalova I, Humenanska V, Haluzik M. Serum concentrations and tissueexpression of a novel endocrine regulator fibroblast growth factor-21 in patientswith type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009 Sep;71(3):369-75.doi: 10.1111/j.1365-2265.2008.03502.x. Epub 2008 Dec 11. PubMed PMID: 19702724. See more on PubMed
  • Mutanen A, Heikkilä P, Lohi J, Raivio T, Jalanko H, Pakarinen MP. Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. J Hepatol. 2014 Jan;60(1):183-90. doi: 10.1016/j.jhep.2013.09.003. Epub 2013 Sep 7.PubMed PMID: 24021426. See more on PubMed
  • Novotny D, Vaverkova H, Karasek D, Lukes J, Slavik L, Malina P, Orsag J.Evaluation of total adiponectin, adipocyte fatty acid binding protein andfibroblast growth factor 21 levels in individuals with metabolic syndrome.Physiol Res. 2014;63(2):219-28. Epub 2014 Jan 8. PubMed PMID: 24397811. See more on PubMed
  • Payne BA, Price DA, Chinnery PF. Elevated serum fibroblast growth factor 21levels correlate with immune recovery but not mitochondrial dysfunction in HIVinfection. AIDS Res Ther. 2013 Nov 19;10(1):27. doi: 10.1186/1742-6405-10-27.PubMed PMID: 24252301; PubMed Central PMCID: PMC3874602. See more on PubMed
  • Reinehr T, Karges B, Meissner T, Wiegand S, Fritsch M, Holl RW, Woelfle J.Fibroblast Growth Factor 21 and Fetuin-A in Obese Adolescents With and WithoutType 2 Diabetes. J Clin Endocrinol Metab. 2015 Aug;100(8):3004-10. doi:10.1210/jc.2015-2192. Epub 2015 Jun 8. PubMed PMID: 26052728. See more on PubMed
  • Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab. 2012Jun;97(6):2143-50. doi: 10.1210/jc.2012-1221. Epub 2012 Mar 21. PubMed PMID:22438225. See more on PubMed
  • Sabaratnam R, Pedersen AJT, Kristensen JM, Handberg A, Wojtaszewski JFP,Højlund K. Intact regulation of muscle expression and circulating levels ofmyokines in response to exercise in patients with type 2 diabetes. Physiol Rep.2018 Jun;6(12):e13723. doi: 10.14814/phy2.13723. PubMed PMID: 29924476; PubMedCentral PMCID: PMC6009776. See more on PubMed
  • Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, KrishnamurthyR, Muthupillai R, Chan L, Bajaj M. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model ofobesity and in a randomised controlled trial. Diabetologia. 2011Dec;54(12):3093-100. doi: 10.1007/s00125-011-2317-z. Epub 2011 Sep 29. PubMedPMID: 21956711; PubMed Central PMCID: PMC3658171. See more on PubMed
  • Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, Ogimoto K, Schwartz MW.Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010 Jul;59(7):1817-24. doi:10.2337/db09-1878. Epub 2010 Mar 31. PubMed PMID: 20357365; PubMed Central PMCID:PMC2889784. See more on PubMed
  • Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, ChanFK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholicsteatohepatitis by combined serum biomarkers. J Hepatol. 2012 Jun;56(6):1363-70. doi: 10.1016/j.jhep.2011.12.025. Epub 2012 Feb 4. PubMed PMID: 22314419. See more on PubMed
  • Spolcová A, Holubová M, Mikulášková B, Nagelová V, Stofková A, Lacinová Z,Jurčovičová J, Haluzík M, Maletínská L, Zelezná B. Changes in FGF21 serumconcentrations and liver mRNA expression in an experimental model of completelipodystrophy and insulin-resistant diabetes. Physiol Res. 2014;63(4):483-90.Epub 2014 Jun 5. PubMed PMID: 24908095. See more on PubMed
  • Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M.Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care. 2009Jan;32(1):126-8. doi: 10.2337/dc08-1054. Epub 2008 Oct 7. PubMed PMID: 18840768; PubMed Central PMCID: PMC2606845. See more on PubMed
  • Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, Drynda K, Lössner U,Blüher M, Stumvoll M, Fasshauer M. Serum fibroblast growth factor 21 levels ingestational diabetes mellitus in relation to insulin resistance and dyslipidemia.Metabolism. 2010 Jan;59(1):33-7. doi: 10.1016/j.metabol.2009.07.003. Epub 2009Aug 21. PubMed PMID: 19699495. See more on PubMed
  • Stepan H, Kley K, Hindricks J, Kralisch S, Jank A, Schaarschmidt W, Schrey S, Ebert T, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Richter J, Fasshauer M.Serum levels of the adipokine fibroblast growth factor-21 are increased inpreeclampsia. Cytokine. 2013 May;62(2):322-6. doi: 10.1016/j.cyto.2013.02.019.Epub 2013 Mar 29. PubMed PMID: 23545215. See more on PubMed
  • Suomalainen A, Elo JM, Pietiläinen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S, Pihko H, Darin N, Õunap K,Kluijtmans LA, Paetau A, Buzkova J, Bindoff LA, Annunen-Rasila J, Uusimaa J,Rissanen A, Yki-Järvinen H, Hirano M, Tulinius M, Smeitink J, Tyynismaa H. FGF-21as a biomarker for muscle-manifesting mitochondrial respiratory chaindeficiencies: a diagnostic study. Lancet Neurol. 2011 Sep;10(9):806-18. doi:10.1016/S1474-4422(11)70155-7. Epub 2011 Aug 3. PubMed PMID: 21820356. See more on PubMed
  • Tanimura Y, Aoi W, Takanami Y, Kawai Y, Mizushima K, Naito Y, Yoshikawa T.Acute exercise increases fibroblast growth factor 21 in metabolic organs andcirculation. Physiol Rep. 2016 Jun;4(12). pii: e12828. doi: 10.14814/phy2.12828. PubMed PMID: 27335433; PubMed Central PMCID: PMC4923231. See more on PubMed
  • Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J,Rissanen A, Suomalainen A, Pietiläinen KH. Liver fat but not other adipositymeasures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab. 2011 Feb;96(2):E351-5. doi: 10.1210/jc.2010-1326. Epub 2010 Dec1. PubMed PMID: 21123446. See more on PubMed
  • Vienberg SG, Brøns C, Nilsson E, Astrup A, Vaag A, Andersen B. Impact ofshort-term high-fat feeding and insulin-stimulated FGF21 levels in subjects with low birth weight and controls. Eur J Endocrinol. 2012 Jul;167(1):49-57. doi:10.1530/EJE-12-0039. Epub 2012 Apr 23. PubMed PMID: 22529197. See more on PubMed
  • Vienberg SG, Jacobsen SH, Worm D, Hvolris LE, Naver L, Almdal T, Hansen DL,Wulff BS, Clausen TR, Madsbad S, Holst JJ, Andersen B. Increasedglucose-stimulated FGF21 response to oral glucose in obese nondiabetic subjectsafter Roux-en-Y gastric bypass. Clin Endocrinol (Oxf). 2017 Jan;86(1):156-159.doi: 10.1111/cen.13241. Epub 2016 Oct 17. PubMed PMID: 27649688. See more on PubMed
  • von Holstein-Rathlou S, BonDurant LD, Peltekian L, Naber MC, Yin TC, ClaflinKE, Urizar AI, Madsen AN, Ratner C, Holst B, Karstoft K, Vandenbeuch A, Anderson CB, Cassell MD, Thompson AP, Solomon TP, Rahmouni K, Kinnamon SC, Pieper AA,Gillum MP, Potthoff MJ. FGF21 Mediates Endocrine Control of Simple Sugar Intakeand Sweet Taste Preference by the Liver. Cell Metab. 2016 Feb 9;23(2):335-43.doi: 10.1016/j.cmet.2015.12.003. Epub 2015 Dec 24. PubMed PMID: 26724858; PubMed Central PMCID: PMC4756759. See more on PubMed
  • Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS,Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in obesity and areindependently associated with the metabolic syndrome in humans. Diabetes. 2008May;57(5):1246-53. doi: 10.2337/db07-1476. Epub 2008 Feb 5. Erratum in: Diabetes.2019 Jan;68(1):235. PubMed PMID: 18252893. See more on PubMed
  • BonDurant LD, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR, Walsh SA,Ornitz DM, Potthoff MJ. FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. Cell Metab. 2017 Apr 4;25(4):935-944.e4. doi:10.1016/j.cmet.2017.03.005. PubMed PMID: 28380381; PubMed Central PMCID:PMC5494834. See more on PubMed
  • Kirmse B, Cabrerra-Luque J, Ayyub O, Cusmano K, Chapman K, Summar M. Plasmafibroblast growth factor-21 levels in patients with inborn errors of metabolism. Mol Genet Metab Rep. 2017 Sep 4;13:52-54. doi: 10.1016/j.ymgmr.2017.04.001.eCollection 2017 Dec. PubMed PMID: 28920014; PubMed Central PMCID: PMC5586549. See more on PubMed
  • Morovat A, Weerasinghe G, Nesbitt V, Hofer M, Agnew T, Quaghebeur G, Sergeant K, Fratter C, Guha N, Mirzazadeh M, Poulton J. Use of FGF-21 as a Biomarker ofMitochondrial Disease in Clinical Practice. J Clin Med. 2017 Aug 21;6(8). pii:E80. doi: 10.3390/jcm6080080. PubMed PMID: 28825656; PubMed Central PMCID:PMC5575582. See more on PubMed
  • Samms RJ, Lewis JE, Norton L, Stephens FB, Gaffney CJ, Butterfield T, SmithDP, Cheng CC, Perfield JW 2nd, Adams AC, Ebling FJP, Tsintzas K. FGF21 Is anInsulin-Dependent Postprandial Hormone in Adult Humans. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3806-3813. doi: 10.1210/jc.2017-01257. PubMed PMID: 28938434; PubMed Central PMCID: PMC5630254. See more on PubMed
  • Seppä S, Tenhola S, Voutilainen R. Fibroblast Growth Factor 21, Adiponectin,and Irisin as Markers of Unfavorable Metabolic Features in 12-Year-Old Children. J Endocr Soc. 2019 Feb 15;3(4):825-837. doi: 10.1210/js.2018-00399. eCollection2019 Apr 1. PubMed PMID: 30963140; PubMed Central PMCID: PMC6446887. See more on PubMed
  • Laeger T, Baumeier C, Wilhelmi I, Würfel J, Kamitz A, Schürmann A. FGF21improves glucose homeostasis in an obese diabetes-prone mouse model independentof body fat changes. Diabetologia. 2017 Nov;60(11):2274-2284. doi:10.1007/s00125-017-4389-x. Epub 2017 Aug 2. PubMed PMID: 28770320; PubMed CentralPMCID: PMC6448882. See more on PubMed
  • Mai K, Boldt A, Hau HM, Kirschfink M, Schiekofer S, Keller F, Beige J, GiannisA, Sack U, Rasche FM. Immunological Alterations due to Hemodialysis MightInterfere with Early Complications in Renal Transplantation. Anal Cell Pathol(Amst). 2019 Mar 25;2019:8389765. doi: 10.1155/2019/8389765. eCollection 2019.PubMed PMID: 31019876; PubMed Central PMCID: PMC6452532. See more on PubMed
  • Saeidi A, Jabbour G, Ahmadian M, Abbassi-Daloii A, Malekian F, Hackney AC,Saedmocheshi S, Basati G, Ben Abderrahman A, Zouhal H. Independent and CombinedEffects of Antioxidant Supplementation and Circuit Resistance Training onSelected Adipokines in Postmenopausal Women. Front Physiol. 2019 Apr 26;10:484.doi: 10.3389/fphys.2019.00484. eCollection 2019. PubMed PMID: 31105587; PubMedCentral PMCID: PMC6499001. See more on PubMed
  • Klímová J, Zelinka T, Rosa J, Štrauch B, Haluzíková D, Haluzík M, Holaj R,Krátká Z, Kvasnička J, Ďurovcová V, Matoulek M, Novák K, Michalský D, Widimský J Jr, Petrák O. FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. Cancers (Basel). 2019 Apr 5;11(4). pii: E485. doi: 10.3390/cancers11040485. PubMed PMID: 30959789; PubMed Central PMCID: PMC6520899. See more on PubMed
  • Song P, Zechner C, Hernandez G, Cánovas J, Xie Y, Sondhi V, Wagner M,Stadlbauer V, Horvath A, Leber B, Hu MC, Moe OW, Mangelsdorf DJ, Kliewer SA. The Hormone FGF21 Stimulates Water Drinking in Response to Ketogenic Diet andAlcohol. Cell Metab. 2018 Jun 5;27(6):1338-1347.e4. doi:10.1016/j.cmet.2018.04.001. Epub 2018 Apr 12. PubMed PMID: 29657029; PubMedCentral PMCID: PMC5990458. See more on PubMed
  • Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RLC, Chow WS,Tso AWK, Lam KSL, Xu A. Erratum. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans. Diabetes2008;57:1246-1253. Diabetes. 2019 Jan;68(1):235. doi: 10.2337/db19-er01c. Epub2018 Nov 19. PubMed PMID: 30455379; PubMed Central PMCID: PMC6302537. See more on PubMed
Summary References (16)

References to Fibroblast Growth Factor 21

  • Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab. 2009 Sep;94 (9):3594-601
  • Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ, Meza-Arana CE, Cruz-Bautista I, Arellano-Campos O, Navarrete-Lopez M, Aguilar-Salinas CA. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol. 2010 Sep;163 (3):469-77
  • Dostalova I, Haluzikova D, Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res. 2009;58 (1):1-7
  • Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, Papezova H, Haluzik M. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab. 2008 Sep;93 (9):3627-32
  • Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab. 2010 Jan;95 (1):369-74
  • Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010 Nov;59 (11):2781-9
  • Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004 Jun;145(6):2594-603. Epub 2004 Feb 19.
  • Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, Moon MK, Lee HK, Kang SW, Han DS, Kim YB, Jang HC, Park KS. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism. 2010 Nov;59 (11):1656-62
  • Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J, Blundell TL. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry. 2004 Jan 27;43(3):629-40.
  • Hero M, Dunkel L, Vaaralahti K, Raivio T. Serum FGF21 in Boys with Idiopathic Short Stature: Relationship to Lipid Profile, Onset of Puberty and Growth*. Clin Endocrinol (Oxf). 2011 Feb 1;
  • Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T, Nielsen S, Pedersen BK. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes. 2009 Dec;58 (12):2797-801
  • Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang da Y, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003 Jul 1;17(13):1581-91. Epub 2003 Jun 18.
  • Jian WX, Peng WH, Jin J, Chen XR, Fang WJ, Wang WX, Qin L, Dong Y, Su Q. Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism. 2012 Jun;61 (6):853-9
  • Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005 Jun;115(6):1627-35. Epub 2005 May 2.
  • Kotulak T, Drapalova J, Kopecky P, Lacinova Z, Kramar P, Riha H, Netuka I, Maly J, Housa D, Blaha J, Svacina S, Haluzik M. Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res. 2011;60 (5):757-67
  • Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W. Serum fibrobl
Related Products Docs